Jon Pilcher’s spare bedroom in Melbourne’s southern suburbs is the unlikely engine room of a $1.3 billion global biotech.
The chief executive of Neuren Pharmaceuticals has overseen two capital raisings and the rapid growth of the company, which has developed the world’s first approved drug to treat Rett syndrome, a neurological disorder disrupting signalling between brain cells mainly in young girls.
Loading…